The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Plain-language summary

This study collects data toward early detection, prevention and novel treatment approaches in people at high risk of pancreatic cancer (pancreatic ductal adenocarcinoma). It enrolls people aged 18 and older who have a pancreatic cyst, an inherited predisposition syndrome, or risk factors such as diabetes, pancreatitis or obesity. It is a study without an assigned phase and is currently active but not recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Intervention

Data collection

Start date

10/6/2022

Estimated completion

7/1/2026

Countries

United States

Related genes

Locations

• Tampa, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* 18 years of age or older
* Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
* Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
* Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.